降脂药物与美国糖尿病患者较低的视网膜病变及眼科干预风险相关
该回顾性队列分析基于美国商业保险理赔数据库,纳入2008至2015年诊断为2型糖尿病的269,782例患者,其中99,233例(37%)接受降脂药物治疗。调整时间-事件分析显示,降脂药物与任何视网膜病变诊断风险降低(HR 0.60,95%CI 0.55-0.65)及任何视网膜病变治疗风险降低(HR 0.81,95%CI 0.78-0.84)相关。
要点
- 降脂药物与任何视网膜病变诊断风险降低相关(HR 0.60,95%CI 0.55-0.65)。
- 降脂药物与任何视网膜病变治疗风险降低相关(HR 0.81,95%CI 0.78-0.84)。
- 非增殖性糖尿病视网膜病变(HR 0.63)、增殖性糖尿病视网膜病变(HR 0.45)、糖尿病黄斑水肿(HR 0.39)风险均降低。
核心结论
- 本研究一致发现,服用降脂药物的患者发生非增殖性糖尿病视网膜病变、增殖性糖尿病视网膜病变或糖尿病黄斑水肿的可能性较低,并有适度证据表明这些患者接受抗VEGF玻璃体腔注射、激光治疗或玻璃体切除术的可能性较低。
- 该研究在美国大型商业理赔数据库中验证了东亚相对同质人群中利用理赔数据库所估计的他汀使用与视网膜病变关联的研究结果。
研究设计与样本
- 回顾性队列分析,数据来自Truven MarketScan商业理赔与 encounters 数据库。
- 人群为2型糖尿病受益人,共分析2008至2015年间诊断为2型糖尿病的269,782例患者。
主要发现
- 99,233例患者(37%)接受降脂药物治疗。
- 服用降脂药物的患者中约6%在糖尿病诊断后记录中有非增殖性糖尿病视网膜病变、增殖性糖尿病视网膜病变或糖尿病黄斑水肿的诊断代码或玻璃体腔注射、平坦部玻璃体切除术或激光治疗的操作代码,而未服用降脂药物的患者为6.5%(P < 0.01)。
- 在2型糖尿病诊断前服用降脂药物的患者进展至任何视网膜病变诊断的可能性较低(HR 0.60;95%CI 0.55-0.65),接受任何视网膜病变治疗的可能性较低(HR 0.81;95%CI 0.78-0.84)。
- 各诊断层面:非增殖性糖尿病视网膜病变 HR 0.63(95%CI 0.57-0.69);增殖性糖尿病视网膜病变 HR 0.45(95%CI 0.37-0.54);糖尿病黄斑水肿 HR 0.39(95%CI 0.33-0.45)。
- 各治疗类别层面:抗VEGF注射 HR 0.81(95%CI 0.78-0.84);激光 HR 0.62(95%CI 0.47-0.81);玻璃体切除术 HR 0.71(95%CI 0.59-0.85)。
关键数值与推荐
- 主要结局指标为任何视网膜病变体征,通过非增殖性糖尿病视网膜病变、增殖性糖尿病视网膜病变或糖尿病黄斑水肿的诊断代码以及视网膜病变治疗(抗VEGF注射、激光治疗和玻璃体切除术)的操作代码测量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the impact of lipid-lowering medications on diabetic retinopathy and diabetic complications requiring intervention in the US population. DESIGN: Retrospective cohort analysis. METHODS: Administrative insurance claims were drawn from the Truven MarketScan Commercial Claims and Encounters databases. Population consisted of beneficiaries with type 2 diabetes mellitus (T2DM). Main outcome measurements were any signs of diabetic retinopathy, as measured by diagnosis codes for nonproliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), or diabetic macular edema (DME) and procedure codes for retinopathy treatments (anti-VEGF injections, laser therapy, and vitrectomy). RESULTS: A population of 269,782 patients diagnosed with T2DM between 2008 and 2015 were analyzed. A total of 99,233 patients (37%) were undergoing treatment with lipid-lowering medications. Approximately 6% of patients taking lipid-lowering medications had a diagnosis code for NPDR, PDR, or DME or a procedural code for intravitreal injections, pars plana vitrectomy (PPV) or laser treatment in their record following diagnosis with diabetes compared to 6.5% of patients who did not take lipid-lowering medications (P < 0.01). In adjusted time-to-event analyses, patients who took lipid-lowering medications prior to diagnosis of T2DM were less likely to progress to any retinopathy diagnosis (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.55-0.65) and less likely to receive any treatment for retinopathy (HR, 0.81; 95% CI, 0.78-0.84). These findings were significant at the aggregate level, at the individual level of diagnosis (NPDR HR, 0.63; 95% CI, 0.57-0.69; PDR HR, 0.45; 95% CI, 0.37-0.54; and DME HR, 0.39; 95% CI, 0.33-0.45), and at the level of each treatment category (anti-VEGF injection HR, 0.81; 95% CI, 0.78-0.84; laser HR, 0.62; 95% CI, 0.47-0.81; and vitrectomy HR, 0.71; 95% CI, 0.59-0.85). CONCLUSIONS: This study found consistent evidence that patients taking lipid-lowering medications were less likely to develop NPDR, PDR, or DME and modest evidence that these patients are less likely to receive intravitreal injections of anti-VEGF medication, laser treatments, or vitrectomy. The study validates the findings of studies that have used claims databases in East Asia in relatively homogeneous populations to estimate an association between statin use and retinopathy, replicating them in a US context in a large commercial claims database.
引用
- Vail D, Callaway NF, Ludwig CA, et al. Lipid-Lowering Medications Are Associated with Lower Risk of Retinopathy and Ophthalmic Interventions among United States Patients with Diabetes. Am J Ophthalmol. 2019. PMID: 31194953. doi:10.1016/j.ajo.2019.05.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。